Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ...

The PALISADE studies are progressing well, with enrollment on track and data release expected in mid-2025 for PALISADE-3 and end of 2025 for PALISADE-4.